News
04-19-2010, 08:50 AM
In an update of the 19,490-patient Study of Tamoxifen and Raloxifene (STAR) P-2 trial in breast cancer prevention, both raloxifene and tamoxifen remain effective options to prevent breast cancer at 81 months of follow-up.
More... (http://www.news-medical.net/news/20100419/Raloxifene-tamoxifen-remain-effective-options-in-prevention-of-breast-cancer-finds-19490-patient-study.aspx)
More... (http://www.news-medical.net/news/20100419/Raloxifene-tamoxifen-remain-effective-options-in-prevention-of-breast-cancer-finds-19490-patient-study.aspx)